NCT05236387View on ClinicalTrials.gov

Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

TerminatedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

May 23, 2023

Study Completion Date

June 30, 2023

Conditions

Breast Cancer

Interventions

DRUG

99m Tc-TM

Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.

Trial Locations (1)

21224

Johns Hopkins Bayview Hospital, Baltimore